A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505863-35-00

Acronym

61186372NSC2007

Enrollment

Registered

2024-03-18

Start date

2024-03-20

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

Brief summary

Incidence of Grade ≥2 DAEIs (Appendix 17: Dermatologic Adverse Events of Interest: Preferred Terms) in the first 12 weeks after initiation of amivantamab and lazertinib treatment

Interventions

DRUGDoxyderma 50 mg

DRUGMINOCIN 50 mg capsule rigide

DRUGDociton® 10 mg Filmtabletten

DRUGChlorhexidine

DRUGMinocyclin-ratiopharm® 100 mg Hartkapseln

DRUGProtopic 0.1% ointment

DRUGJNJ-61186372

DRUGDalacin 10 mg emulsión cutánea

DRUGOpzelura 15 mg/g cream

DRUGDoxy-M-ratiopharm® 100 mg Tabletten

DRUGJNJ-73841937

DRUGDoxy-M-ratiopharm 100 mg tabletės

DRUGTimolol 0

DRUG5 % AT - 1 A Pharma

DRUG5 mg/ml Augentropfen

DRUGLösung

DRUGClobeGalen 500 Mikrogramm/g Shampoo

DRUGZink Verla® 10 mg

DRUGFilmtabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of Grade ≥2 DAEIs (Appendix 17: Dermatologic Adverse Events of Interest: Preferred Terms) in the first 12 weeks after initiation of amivantamab and lazertinib treatment	—

Countries

France, Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026